Biotech Values

[DewDiligence]

Teva forecasts $3.7-3.9B of worldwide Copaxone sales in 2013, which is a slight decrease from 2012. Teva has not given guidance on US Copaxone sales, specifically; however, if the historical 74% of sales in the US holds, then Teva expects 2013 US Copaxone sales of about $2.9B. The actual amount will depend on Copaxone price increases (which are a near certainty) and on competition from BG-12 and other oral agents.

Source: http://www.sec.gov/Archives/edgar/data/818686/000115752312006239/a50493505.htm

p.s. Copaxone has a worldwide gross margin of 90%, according to the above.